European Consortium Developing Cancer Screening System for the Gastrointestinal Tract

Industry leaders in imaging, biosensing technologies and ultra-low power design join in the development of PillCam™ Capsule Endoscope with molecular diagnostics

OTTAWA, CANADA, January 17, 2007 – A European consortium, comprised of leading European technology companies, research institutes and universities, announced that it has received approval from the European Commission of the Sixth EU Framework Program of Research and Technological Development (“FP6 commission”) to develop an integrated imaging–biosensing system to screen for cancer of the gastrointestinal (GI) tract. The “Nano-based capsule-Endoscopy with Molecular Imaging and Optical biopsy” (NEMO) project kicked off in Tel-Aviv at the end of November.

In addition to Given Imaging (Israel), the project coordinator, the consortium includes Zarlink Semiconductor (Sweden and UK), Fraunhofer Institute for Biomedical Engineering, Israelitic Hospital and Indivumed (Germany), Imperial College of Science, Technology and Medicine (London, England), ITC-irst Research Institute (Italy), The Hebrew University of Jerusalem, Novamed and Ernst &Young (Israel). The NEMO Group will invest €4.7 million over the next three years, of which the European Commission will contribute €2.8 million.

The objective of the NEMO project is to increase patient compliance with currently recommended screening guidelines by developing an advanced cancer screening system that is patient-friendly, highly sensitive and specific for early detection of cancer. To achieve this NEMO will converge optical technologies with Nano-technologies, biosensing and maneuvering technologies to create a unique PillCam capsule endoscope capable of secretion analysis and the detection of marked and deep tissue disorders. The consortium believes the combination of the image and molecular analysis to mark the tumor may provide a novel and effective medical device for mass screening for GI cancer.

"We are proud to advance our research in the biosensing field with such leading research and industrial organizations,” said Elisha Rabinovitz, DSc, Chief Scientist of Given Imaging and the consortium coordinator. “This project further exemplifies Given’s commitment to develop new and innovative solutions to help physicians treat their patients and could represent a revolutionary platform of biopsy free procedures.”

About Zarlink Semiconductor

For over 30 years, Zarlink Semiconductor has delivered semiconductor solutions that drive the capabilities of voice, enterprise, broadband and wireless communications. The Company’s success is built on its technology strengths including voice and data networks, optoelectronics and ultra low-power communications. For more information, visit www.zarlink.com.

About Given Imaging Ltd.

Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company's technology platform is the PillCam™ Platform, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient, a sensor array, data recorder and RAPID® software. Given Imaging has three commercially available capsules: the PillCam SB video capsule to visualize the entire small intestine which is currently marketed in the United States and in more than 50 other countries; the PillCam ESO video capsule to visualize the esophagus; and the Agile™ patency capsule to determine the free passage of the PillCam capsule in the GI tract. The PillCam COLON video capsule to visualize the colon has been cleared for marketing in the European Union, and multi-center clinical trials are underway in Europe and the U.S. A capsule to visualize the stomach is under development. More than 400,000 patients worldwide have benefited from the PillCam capsule endoscopy procedure. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel; it has direct sales and marketing operations in the United States, Germany and France, and local offices in Japan, Spain and Australia. For more information, visit http://www.givenimaging.com.

Shareholders and other individuals wishing to receive, free of charge, copies of the reports filed with the U.S. Securities and Exchange Commission and Regulatory Authorities, should visit the Company’s web site at www.zarlink.com or contact Investor Relations.

Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and assumptions include, among others, the following: rapid technological developments and changes; our ability to continue to operate profitably and generate positive cash flows in the future; our dependence on our foundry suppliers and third-party subcontractors; order cancellations and deferrals by our customers; increasing price and product competition; and other factors referenced in our Annual Report on Form 20-F. Investors are encouraged to consider the risks detailed in this filing.

- 30 -

Zarlink and the Zarlink Semiconductor logo are trademarks of Zarlink Semiconductor Inc.

For more information:

Edward Goffin
Media Relations
613 270-711
edward.goffin@zarlink.com

Mike McGinn
Investor Relations
613-270-7210
mike.mcginn@zarlink.com

Home

Site Guide

Site Terms & Conditions

Privacy/Security Statement

Feedback

Trademarks